{"id":"NCT04177108","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer","officialTitle":"A Phase III, Double-blind, Placebo-controlled, Randomized Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-25","primaryCompletion":"2023-02-28","completion":"2023-02-28","firstPosted":"2019-11-26","resultsPosted":"2024-03-27","lastUpdate":"2024-03-27"},"enrollment":242,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Triple-Negative Breast Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab","otherNames":[]},{"type":"DRUG","name":"Ipatasertib","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Placebo for Atezolizumab","otherNames":[]},{"type":"DRUG","name":"Placebo for Ipatasertib","otherNames":[]}],"arms":[{"label":"Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel","type":"EXPERIMENTAL"},{"label":"Cohort 1 Arm B: Ipatasertib + Placebo + Paclitaxel","type":"EXPERIMENTAL"},{"label":"Cohort 1 Arm C: Placebo + Placebo + Paclitaxel","type":"EXPERIMENTAL"},{"label":"Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel","type":"EXPERIMENTAL"},{"label":"Cohort 2 Arm B: Placebo+ Atezolizumab + Paclitaxel","type":"EXPERIMENTAL"}],"summary":"This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","timeFrame":"From Randomization to disease progression, study completion, or death (up to 39 months)","effectByArm":[{"arm":"Cohort 1 Arm A: Ipatasertib + Atezolizumab + Paclitaxel","deltaMin":7.1,"sd":null},{"arm":"Cohort 1 Arm B: Ipatasertib + Atezolizumab Matching Placebo + Paclitaxel","deltaMin":5.6,"sd":null},{"arm":"Cohort 1 Arm C: Ipatasertib Matching Placebo + Atezolizumab Matching Placebo + Paclitaxel","deltaMin":3.7,"sd":null},{"arm":"Cohort 2 Arm A: Ipatasertib + Atezolizumab + Paclitaxel","deltaMin":5.6,"sd":null},{"arm":"Cohort 2 Arm B: Ipatasertib Matching Placebo+ Atezolizumab + Paclitaxel","deltaMin":5.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0098"},{"comp":"OG001 vs OG002","p":"0.2396"},{"comp":"OG003 vs OG004","p":"0.9809"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":182,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Colombia","Costa Rica","Czechia","Denmark","Finland","France","Greece","Hong Kong","India","Israel","Italy","Japan","Mexico","New Zealand","Peru","Poland","Portugal","Romania","Russia","Singapore","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":43},"commonTop":["Diarrhoea","Constipation","Alopecia","Nausea","Rash"]}}